^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective androgen receptor modulator

    Related drugs:
    Apply
    Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (NCT05573126)
    Phase 1/2
    Ellipses Pharma
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/11/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    HER-2
    |
    HER-2 negative
    |
    everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)
    Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/19/2024
    Initiation :
    06/01/2017
    Primary completion :
    10/28/2020
    Completion :
    08/16/2022
    HER-2 • ER • PGR • AR
    |
    HER-2 negative • AR positive • ER expression • PGR expression
    |
    Keytruda (pembrolizumab) • Ostarine (enobosarm)
    Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer (NCT02463032)
    Phase 2
    GTx
    Completed
    Last update posted :
    12/09/2020
    Initiation :
    08/01/2015
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    HER-2 • ER • AR
    |
    ER positive • HER-2 negative • AR positive
    |
    Ostarine (enobosarm)